SAN DIEGO, May 20, 2019 /PRNewswire/ -- Shareholder
Rights Law Firm Johnson Fistel, LLP is investigating potential
violations of federal and state laws by Bellicum Pharmaceuticals,
Inc. (NASDAQ: BLCM) ("Bellicum") and certain of its
officers.
Last year a securities class action lawsuit was filed on behalf
of purchasers of the securities of Bellicum from May 8, 2017 and January
30, 2018, (the "Class Period"). According to the lawsuit,
defendants during the Class Period made materially false and/or
misleading statements and/or failed to disclose that: (1) a
substantial undisclosed risk of encephalopathy was associated with
the Bellicum's lead product candidate, BPX-501; and (2) as a
result, Bellicum's public statements were materially false and
misleading at all relevant times.
If you are a long-term shareholder of
Bellicum continuously holding shares before
May 8, 2017, you may have
standing to hold Bellicum harmless from the alleged harm
caused by the officers and directors of the Company by making them
personally responsible. You may also be able to assist in reforming
the Company's corporate governance to prevent future
wrongdoing.
If you are interested in learning more about your legal
rights and remedies, please contact Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If you
email, please include your phone number.
Additionally, you can [click here to join this action].
There is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/blcm-alert-johnson-fistel-llp-announces-investigation-of-bellicum-pharmaceuticals-inc-long-term-investors-encouraged-to-contact-firm-300853100.html
SOURCE Johnson Fistel, LLP